Member Info for doggo

Sellers obviously aren’t as confident as the owner of Atlassian pumping $10 million of his own money into Juvenescence. Or the owner of ICAP one of the UK’s super rich putting the same amount in.
The Atlassian guy owns the most expensive house in Australia.

Medican4u.co.uk
Medican4u is a GPhC registered online pharmacy, specialising in the supply of bespoke medicines for private prescriptions across the UK. With our in-house state-of-the-art MHRA approved manufacturing facility, along with a vastly experienced team and a comprehensive quality management system, Medican4u ensures that specific patient needs are met every single time.

We employ a team of highly trained and experienced on-site pharmacists, pharmacy technicians, data scientists and healthcare professionals who are all focused on providing you with quality medicines and a service second-to-none.

Has no bearing on real value.

Stop with the nonsense. Just look at the direction the last 3 trading days and the stacking news.

What the MMs did there.
Hold or buy tomorrow ladies

We will get a nice surprise with cryptologic.

Juvenescence will close a monster Series C round with a handful of investors who are set to cover the whole round themselves.

The company is the world’s best funded anti-aging and longevity platform. Series B valued the company >$500 million

#FFWD bought series A

It’s HUGE

We have a 0.4% interest in it. Not to be sniffed at when it’s a $60 million MCAP on NYSE.

This isn’t in our official NAV by the way

and Chilston fills the board with this. He’s bought a woman for unknown price to add to his collection of other women that he’s surrounded with.

He will tell us about the note she wrote before she escaped written in blood...

Give him his 5.4

This is a unique new level deramping.

You bought her? How much did you pay for her?

She realised you were a freak and ran.

5.4 Lol

The resident derampers today? It’s very quiet.
Fully expect to see Chilston rally his troops later

I would read the above RNS. Then find out what Salv hold.

I’d want to release news pre IPO

The whole jigsaw is there Quint.

Would it be possible to get Bristol Myers Squib to test 4 portage biotech assets with their drugs if the CEO of Portage was a core member of Bristol-Myers Squibb’s Strategic Transactions Group evaluating and executing licensing agreements, mergers and acquisitions, clinical collaborations, and the company’s immuno-oncology strategy.

Or if the Portage Chief Scientific Officer was also the former Head of Oncology Discovery Research at Bristol-Myers Squibb.

Or the Portage V.P. of Project Management & Operations Senior Director of Oncology Project Management and Clinical Operations, having responsibility across the BMS portfolio ranging from discovery to life cycle management. During his time at BMS, Steve directly managed or provided development oversight for a number of the BMS immune-oncology assets, including Yervoy and Opdivo.

What if we knew that the 4 Portage assets were to be tested on Yervoy and Opdivo specifically?

What if we knew that Opdivo was the 4th largest $ drug in the world.

Asking for a friend...

The buying and reintroduce selling. We’ve a little boy on this board who was waiting for Santa to give him 5.4p to enable him to reach TR1 status.

We may have tears on the coming big day.

Using Factom.inc’s Harmony product to protect document integrity.

A Berkshire Hathaway company also uses Factom

Thomson Reuters are invested in Avanta